ADIM
CRL icon

Alpha DNA Investment Management’s Charles River Laboratories CRL Stock Holding History

Alpha DNA Investment Management’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-18
Closed -$4K – 704
2020
Q4 		$4K Buy
+18
New +$4.29K ﹤0.01% 386

Other funds holding CRL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Alpha DNA Investment Management's CRL Position: Q1 2021 in Review

Alpha DNA Investment Management sold out of Charles River Laboratories (CRL) in Q1 2021, closing a stake of 18 shares — an estimated $4K sold.

Alpha DNA Investment Management first reported a position in CRL in Q4 2020 and held it in 1 quarter. The position peaked at $4K in Q4 2020. 561 funds tracked by Wall St. Rank hold CRL as of Q1 2021.

  • Alpha DNA Investment Management reported no remaining Charles River Laboratories position as of Q1 2021 after selling out during the quarter.
  • Alpha DNA Investment Management sold 18 Charles River Laboratories shares in Q1 2021, an estimated $4K.
  • Alpha DNA Investment Management first reported a position in Charles River Laboratories in Q4 2020 and held it in 1 quarter.
  • Alpha DNA Investment Management's Charles River Laboratories position peaked at $4K in Q4 2020.
  • 561 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2021.

Based on Alpha DNA Investment Management's 13F filing for Q1 2021, filed 12 May 2021.